ESMO-MCBS Scale Evaluates Clinical Benefit of Radiotherapy in Non-Small Cell Lung Cancer Treatment

Strategic Insights -

Studies have shown that radiotherapy is a valuable treatment option for patients with extracranial oligometastatic non-small cell lung cancer (NSCLC), with significant improvements in survival rates. Researchers at Dartmouth-Hitchcock Medical Center evaluated the clinical benefit of radiotherapy in NSCLC patients using the European Society of Medical Oncology (ESMO) magnitude of clinical benefit scale (MCBS) version 1.1. The study found that the addition of stereotactic body radiation therapy to standard-of-care chemotherapy resulted in substantial improvements in survival, with 9 out of 10 prospective single-arm studies receiving a score of 3 using form 3, indicating progression-free survival exceeding 6 months.

Key Takeaways:

  • The ESMO-MCBS scale version 1.1 is an evaluation tool for assessing the clinical benefit of treatments in cancer research studies.
  • The study applied the ESMO-MCBS v1.1 to 25 studies, including 10 prospective single-arm studies, to evaluate the clinical benefit of radiotherapy in NSCLC treatment.
  • The use of local radiation therapy in the treatment of extracranial oligometastatic NSCLC is associated with a substantial clinical benefit, according to the ESMO-MCBS v1.1.
  • Radiation therapy was comparable to established targeted therapies such as pembrolizumab and osimertinib in combination with standard chemotherapy.
  • The study concluded that the quality-of-life improvements found in future trials would potentially increase the MCBS score.

Statistics:

  • 25 studies were evaluated using the ESMO-MCBS v1.1, including 10 prospective single-arm studies.
  • 9 out of 10 prospective single-arm studies received a score of 3 using form 3, indicating progression-free survival exceeding 6 months.
  • 100% (10/10) of prospective single-arm studies exceeded a score of 3 using form 3.
  • 9 studies out of 10 prospective single-arm studies were associated with a substantial clinical benefit, as indicated by a score of 3 or higher using form 3.

Sources:

  • Evaluation of the European Society of Medical Oncology-Magnitude of Clinical Benefit Scale Version 1.1 for the Treatment of Extracranial Oligometastatic Non-Small Cell Lung Cancer With Radiosurgery. Practical Radiation Oncology, 2025. (Elsevier - www.elsevier.com; Practical Radiation Oncology - www.journals.elsevier.com/practical-radiation-oncology/)
  • NewsRx. New Findings from Dartmouth-Hitchcock Medical Center in the Area of Non-Small Cell Lung Cancer Reported (Evaluation of the European Society of Medical Oncology-Magnitude of Clinical Benefit Scale Version 1.1 for the Treatment of Extracranial ...). Cancer Weekly. October 14, 2025; p 1021.